August 18, 2021 01:17 PM EDT
FDA+

FDA+ roundup: New un­ti­tled let­ter for web ads with­out risk in­fo; PAN­DAs and reg­u­la­to­ry un­cer­tain­ty

Zachary Brennan

Senior Editor

The FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion on Tues­day is­sued its third un­ti­tled let­ter of the year to Eton Phar­ma­ceu­ti­cals, ar­gu­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

FDA puts two Chi­nese API mak­ers on im­port alert af­ter failed in­spec­tions

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times